Allergy & Immunology
Expert discussions on allergic conditions, immunodeficiencies, drug hypersensitivity, and immunotherapy approaches.
Recent Discussions
How are you choosing between Xolair, Dupixent or Rhapsido for patients with CSU?
Patient choice, many patients prefer a monthly shot as opposed to BOD meds every day or even q 2 weeks shot; also, co-morbidities--FA, eczema...
What are the implications of checking post-vaccine titers after administration of Prevnar 20 compared to PPSV23?
The landscape of pneumococcal vaccine choices has undergone considerable change in the past few years. Notably, the expanded pneumococcal conjugate vaccines (PCV15, PCV20, PCV21) approved for a broad age range which provide almost overlapping coverage of the pure polysaccharide pneumococcal vaccine ...
Are there specific conventional DMARDs and/or biologics that are contraindicated in patients with alpha-gal allergy?
Here is a Q&A from AAAAI (American Academy of Allergy, Asthma and Immunology) addressing this question for etanercept and other monoclonal antibodies that are manufactured in cell lines that glycosylate with alpha-gal. The author concludes, "The risk is not zero, but likely very low".
Which patient factors drive you to pursue patch testing in the workup of chronic hand eczema?
Seasonal hand eczema occurring only during the cold season is usually irritant and best addressed by minimizing hand washing and using cotton under occlusive gloves with frequents changes for wet work. Careful examination for signs of psoriasis and anti-synthetase syndrome is important. Next step is...
Would you still restrict live viral vaccines in a pediatric patient with CD4 count <500 even though they had previously tolerated them and before CD4 testing was obtained?
No. Generally, I follow the guidelines of CD4>400, CD8>200, and look at the response of other vaccines like Tetanus.
Which biologics for asthma have data regarding mucus plugging?
There have been multiple studies on biologics investigating the effects on mucus plugging (as measured by the CT mucus plug score of the number of pulmonary segments with a mucus plug, established by Dunican et al., PMID 29400693). In these studies, high mucus plug scores correlate with T2 high biom...
Do you see GLP-1 receptor agonists as a potential adjunctive therapy in patients with T2-low asthma and obesity who remain symptomatic on ICS-LABA, prior to escalation to tezepelumab?
Initial research is promising but needs more data.
Are there best practices for integrating pollen, wildfire smoke, and AQI data into asthma/allergic rhinitis action plans?
Living in northern Calif, we frequently incorporate this topic into our patient discussions. We advise virtually all of our asthmatic pts to have a high-quality HEPA air purifier available because they frequently become hard to get when the air quality decreases.
Are you managing chronic urticaria/angioedema any differently if the patient is only/predominantly presenting with urticaria or angioedema?
The mechanism is similar for urticaria and histamine-induced angioedema, so I would expect a similar response. The evidence to support the use of montelukast for U/A is slim, but there are some supporting data. Nonetheless, the newest WAO guideline does not suggest an addition to the therapeutic pyr...
In patients with severe asthma who are candidates for biologics, do you put them on an ICS/LABA/LAMA rather than high dose ICS/LABA?
It depends on the patient and their co-morbidities. For poor compliance, Trelegy can be a game-changer due to ease of administration.